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a  b  s  t  r  a  c  t
Despite  condoms  being  cheap  and  effective  in  preventing  HIV,  there  remains  an  8  billion  shortfall  in
condom  use  in risky  sex-acts.  Social  marketing  organisations  apply  private  sector  marketing  approaches
to  sell  public  health  products.  This  paper  investigates  the  impact  of  marketing  tools,  including  promo-
tion  and  pricing,  on demand  for male  and  female  condoms  in 52  countries  between  1997 and  2009.  A
static  model  differentiates  drivers  of demand  between  products,  while  a dynamic  panel  data  estima-
tor  estimates  their  short-  and  long-run  impacts.  Products  are not  equally  affected:  female  condoms  are
not affected  by  advertising,  but  highly  affected  by  interpersonal  communication  and  HIV  prevalence.
Price  and  promotion  have  signiﬁcant  short-  and long-run  effects,  with  female  condoms  far  more  sensi-eywords:
dvertising
onsumer demand
IV prevention
ynamic panel data estimators
ondoms
ow and middle income countries
tive  to price  than  male  condoms.  The  design  of optimal  distribution  strategies  for  new  and  existing  HIV
prevention  technologies  must  consider  both  product  and  target  population  characteristics.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).. Introduction
Since the onset of the HIV epidemic around 50 million HIV infec-
ions have been averted by the use of condoms (Stover, 2014).
ondoms are cheap and highly cost-effective. However, in 2012,
.3 million people still became infected with HIV (Joint United
ations Programme on HIV/AIDS, 2013). A recent UNAIDS meeting
dentiﬁed a condom gap of over 8 billion condoms, i.e. the difference
etween the UNAIDS target condom use in risky sex acts and actual
se, with an annual use of just eight condoms per sexually active
erson in sub-Saharan Africa (Deperthes, 2014). Though there is
ew optimism that bio-medical tools exist to stem the HIV epi-
emic in the form of anti-retroviral (ARV)-based HIV prevention
Fauci and Folkers, 2012), these are service intensive, expensive,
nd not widely available. Achieving high levels of uptake of pre-
entive interventions is particularly challenging because it requires
 change in behaviour among populations who may  not perceive
hemselves to be at risk, feel ill or face barriers, real or perceived, to
∗ Corresponding author. Tel.: +442079272271.
E-mail addresses: Fern.Terris-Prestholt@lshtm.ac.uk (F. Terris-Prestholt),
.Windmeijer@bristol.ac.uk (F. Windmeijer).
ttp://dx.doi.org/10.1016/j.jhealeco.2016.04.001
167-6296/© 2016 The Authors. Published by Elsevier B.V. This is an open access article uaccessing products and product support. For condoms and new HIV
prevention products to fulﬁl their public health potential they must
be used widely and effectively; this requires both ensuring consis-
tent and accessible condom supplies and demand creation activities
such as mass media advertising and inter-personal communication
(IEC) promotion approaches.
Though public sector distribution may  be free or very cheap
for consumers to access public health products, it has a number
of potential drawbacks such as limited opening hours, inconsis-
tent supply, and low perceived quality of products and services
(Hanson et al., 2001). Where private sector markets do exist, prices
are often too high for those who need the products most. Addition-
ally, competitive prices will be above the socially optimal price for
HIV prevention because they are not capturing external beneﬁts
to society attributable to reductions in HIV. To ﬁll this gap, social
marketing organisations have been active for decades, initially dis-
tributing subsidised contraceptives including condoms, and more
recently expanding to a range of public health commodities and
services, such as mosquito nets, voluntary counselling and testing
services, and male and female condoms for HIV prevention.
Social marketing is the application of private sector demand cre-
ation tools to stimulate positive behaviour change (Kikumbih et al.,
2005). In particular, consideration is given to the four Ps: product,
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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et al., 2014; Thornton, 2008), staying free from sexually transmitted
infections (de Walque et al., 2012; Galárraga et al., 2014) or volun-
tary medical male circumcision (Thirumurthy et al., 2014). While08 F. Terris-Prestholt, F. Windmeijer / Jour
romotion, price and place (Grier and Bryant, 2005). Branded
roducts aim to segment the market and appeal to different user
roups. Promotion applies both generic advertising to increase the
verall market size as well as branded advertising to appeal to
ifferent user groups, and interpersonal communication strategies.
ifferentially priced products allow for cross-subsidisation of high
o low priced products, with the higher priced products capturing
ore of the consumer surplus, whilst providing a low-end product
o ensure broad access. Additionally, having a sufﬁciently low,
ut positive, price aims to instil a sense of value and has been
hown to have lower wastage associated with freely distributed
ondoms (Chapman et al., 2012). Subsidised products tend to be
laced within the private sector retail distribution networks to
ncrease outlets, while being sold by retailers for a proﬁt, to ensure
onsistent supply and sustainability. In many countries, social mar-
eting is now the dominant source of condom supply (Chapman
t al., 2012). Because social marketing applies traditional demand
timulation tools to public health, while public sector distribution
enerally does not, it provides an opportunity for studying the
ffectiveness of these tools for stimulating demand for new and
xisting HIV prevention products, in the absence of private mar-
ets. Understanding drivers of demand for the male and female
ondom not only informs programmes on how to better stimulate
emand for existing products, it also provides lessons that can
otentially be applied to the introduction of both new single ARV
ased HIV prevention products and multi-purpose products that
revent both HIV and other infections or unwanted pregnancies.
No recent studies have addressed these questions. Brent (2009)
stimated individual conditional demand for social marketing con-
oms in Tanzania and found a price elasticity around 1 with a strong
nﬂuence of quality on willingness to pay, but did not allow price
lasticity to vary by gender, though 86% of respondents (condom
urchasers) were men. Sweat et al. (2012) reviewed the litera-
ure on the contribution of condom social marketing on condom
se and their meta analysis showed that, though the evidence
s weak, in particular for estimating the cumulative effect over
ime, exposure to a condoms social marketing programme doubled
eported condom use among the general population. Differences in
esponsiveness between contraceptive products targeting men  and
omen have been explored. A few studies provide some guidance
s to the effect of social marketing on male condoms and oral con-
raceptive demand and they showed that the demand for products
esponded differently to the same stimulation tools. For exam-
le, Boone et al. (1985) showed that male condom demand was
uch more sensitive to changes in prices and advertising expendi-
ures than oral contraceptive demand. Meekers and Rahaim (2005)
ooked at the impact of market environment and showed that,
hile male condom demand reacts consistently to variables repre-
enting country level socio-economic context, oral contraceptives
ere not signiﬁcantly inﬂuenced by these in most of their anal-
ses. Ciszewski and Harvey (1995) showed that condoms had
uch larger and quicker declines in sales than oral contracep-
ives following price increases in Bangladesh. More speciﬁcally
or male and female condoms, a few important product and pro-
ramme  differences suggest potential differences in their demand
esponses. Firstly, male condoms have long been distributed and
sed as contraceptives, with the additional beneﬁt of reducing
he risk of STI and later HIV. Male condoms have generally been
istributed through a wide range of distribution channels with
inimal training and support for the users. Female condoms were
eveloped as a method that women could use to protect themselves
rom HIV and pregnancy (Warren and Philpott, 2003). However,
emale condoms need signiﬁcant introductory support: interper-
onal communication and peer support groups have been shown
o help women continue to use female condoms (Vijayakumar et al.,
006). Health Economics 48 (2016) 107–120
While these studies have shed some light on how marketing
tools can stimulate demand, they have methodological weaknesses.
None have tested for differences in drivers of demand between
HIV prevention products, nor have any accounted for the fact that
behaviour adjusts slowly to interventions and therefore analyses
that fail to account for this may  obtain biased estimates of the
responsiveness of condom demand to changes in marketing tools
and their long-run effects.
In this paper we explore the drivers of demand for HIV pre-
vention products targeted at women  and men (i.e. female and
male condoms), using unique expenditure and sales data from
Population Services International (PSI), a large international social
marketing organisation, in an unbalanced panel of 52 countries
over 11 years: 1997–2009.1 To the best of our knowledge, this
is the ﬁrst study to conduct an economic/econometric analysis of
the drivers of demand for female and male condoms. In addition
to price, both programmatic demand creation tools (mass media
advertising; ‘information, education, and communication’ (IEC) and
programme effort), as well as the broader country context (income
levels and adult HIV prevalence) are considered as potential drivers
of demand. A dynamic panel data estimator is used to identify the
short- and long-run impact of advertising, price and programme
effort (stafﬁng). This study can guide programmes on how best
to allocate funds across their social marketing tools to maximise
uptake and to inform programming of new HIV prevention prod-
ucts.
Broadly speaking this paper belongs to the advertis-
ing/promotion, and product/service use literature and is hence
close in spirit to some papers in the health economics literature.
Avery et al. (2012) study the impact of direct-to-consumer adver-
tising on antidepressant use in the US, and similarly to this paper,
they make a comparative analysis of female and male use of the
product. Windmeijer et al. (2006) examine the responsiveness of
general practitioners to promotional activities for ethical drugs
by pharmaceutical companies in the Netherlands. Ridley (2015)
investigates price and advertisement elasticities of demand in
the US drug market. Dave and Saffer (2013) show that in the
USA smokeless tobacco advertising both increases the market
demand (primary demand) as well as shifting existing users
to the advertised brand. Moreover they show taxes (i.e. higher
prices) have a differential effect, reducing demand more among
younger male smokers and lower educated individuals. These
papers are all in high income settings and in the context of proﬁt
maximising ﬁrms. Our paper thus complements the economics of
advertising literature by presenting evidence on a very different
type of product, in resource limited settings and for a non-proﬁt
organisation aiming to maximise output.
There is a growing interest in the economics of HIV, with a body
of papers addressing the interaction between HIV and the economy,
or other structural factors such as schooling, gender based vio-
lence, risky sexual behaviour and labour force participation (Alsan
and Cutler, 2013; Baranov et al., 2015; Chin, 2013; Francis, 2008;
Galarraga et al., 2010; Oliva, 2010; Oster, 2012; Wilson, 2012).
Many of these studies raise the challenge of establishing causality
due to endogeneity issues, and address this using an instrumental
variables approach. As another approach to establishing causality,
economists have introduced randomised control trials in particular
to test the impact of incentives on HIV prevention, such as keep-
ing girls in school for longer (Baird et al., 2012), HIV testing (Baird1 2005 and 2006 data were not collected centrally and were therefore not available
for  this analysis.
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n general ﬁnancial incentives do induce behaviour change in the
hort-run, the impact is not consistent on male and female trial
articipants, and the long-run impacts are yet to be assessed. It is
n estimating the long-run impact of marketing tools on behaviour
hange (condom use) that this paper contributes to the literature
n the economics of HIV.
The remainder of the paper is organised as follows. Section 2
ntroduces the conceptual framework for analysing demand, espe-
ially the impact of demand creation tools on sales. Section 3
escribes the data and Section 4 outlines the econometric approach.
ection 5 presents and discusses the results and Section 6 con-
ludes.
. A model of male and female condom demand
The starting point for this analysis is the basic relationships
nderlying an aggregate demand model, where the quantity of a
ood demanded is a function of its price, the price of its substitutes
or complements),2 and income. Quantity demanded is proxied by
ggregate country level male and female condom social marketing
ales by PSI. Price is set by country ofﬁces with the aim of high lev-
ls of distribution while aiming for sustainability and low wastage
ather than being determined by market forces. Income is proxied
y GDP per capita.
Given our interest in the effect of demand stimulation tools, the
atural starting point is a generic model of the impact of advertise-
ent on sales. The most common dynamic approach to estimating
dvertising impact is to specify Koyck’s inﬁnite geometric distribu-
ive lag model (Koyck, 1954), given by
n(qt) =  ˛ +
∑
j
ˇj ln(Xjt) +  ln(qt−1) + εt,
here qt is condom sales in period t and the X
j
t are variables impact-
ng the quantity of condoms sold.  is a coefﬁcient representing
he habit persistence/speed of adjustment and εt is a random error
erm. In this model  lies between 0 and 1. If  is 0, past experience
as no impact on current purchasing decisions; if  is 1, the process
s non-stationary. A larger  implies slower adjustment to external
timuli.
The short-run marginal effects of the explanatory variables
advertising and other external stimuli) are represented by ˇ, and
he long-run marginal effect is given by
ˇ
(1 − ) (1)
In the case of advertisement, the expression in (1) is commonly
eferred to as ‘carryover’ or ‘goodwill’. To estimate how long it takes
or 90% of the effect to have occurred, we use the 90% duration
nterval deﬁned by Clarke (1976) asln(1 − 0.9)
ln()
)
− 1 (2)
2 Though we would have liked to examine the substitute market in detail, the
ubstitute markets are not well deﬁned in this case. Conceptually substitutes for
ondoms are both contraceptives and HIV prevention products. Alternatively these
ould be more narrowly deﬁned as female condoms as substitutes for male condoms
nd vice versa. However, the full country level aggregate distribution of each was
ot  available for this analysis. An alternative approach would be to deﬁne it more
peciﬁcally as socially marketed products. Prices for social marketing male condoms
ere available as the substitute market for female condoms; for male condoms this
pproach would result in a very large loss of observations: only 25–50% of condoms
istributing male condoms also distribute female condoms. An alternative deﬁnition
f  the substitute market for male condoms could be to deﬁne a dummy  variable for
he availability of female condoms in the social marketing method mix. Inclusion of
his is explored in the robustness checks presented in Table A6. Health Economics 48 (2016) 107–120 109
As we  are using logarithmic transformations of the variables,
the marginal effects are the short- and long-run elasticities.
In addition, the following determinants of condom demand are
included. Promotion is explored as a composite of mass media
advertising and ‘information, education, and communication’ (IEC)
expenditures as well as in its disaggregated forms. As programmes
can increase the quantities sold in various ways, including expand-
ing distribution systems and improving the consistency of supply,
programme effort (proxied by PSI local salary expenditures) is
included. Acceptability and use of innovations (new products)
increase with exposure (Bass, 1969; Rogers, 1962), we therefore
include a measure of exposure called product maturity, i.e. the num-
ber of years each product has been sold. Although condoms can be
used as a contraceptive, they are also an HIV prevention technology
and their use is thus likely to be related to HIV-risk, represented by
adult HIV prevalence.  In contrast to a typical demand function, the
dependent variable is not individual condom demand, but rather
aggregate country level demand, making the size of the market,
i.e. population size, important. As an issue of special interest, we
will examine whether the relationship under discussion differs by
product type: female versus male condoms.
3. Data
The data consist of country level PSI ﬁnancial accounts used
for routine programme monitoring, supplemented by the World
Bank’s World Development Indicators (WDI)  (World Bank, 2006).
Though PSI distributes a wide variety of public health products,
this analysis focuses exclusively on male and female condom dis-
tribution. We have a total of 385 and 133 observations on male
and female condoms, respectively. The sample includes countries
in Africa, Latin America, Asia and Eastern Europe. The sample used
in the static estimation contains 382 data points for male condoms
and 133 for female condoms. The dynamic estimator requires at
least three years of data to obtain one observation, because of the
need for lags. The dynamic estimation thus had 280 male condom
observations and 85 female condom observations.
Aggregate condom demand is proxied by country level sales of
social marketing male and female condoms in an unbalanced panel
of 633 countries over the period 1997–2009. The deﬁnition and
descriptive statistics of each variable are presented in Table 1. Mean
male condom sales are 100 times larger than mean female condom
sales. Within this dataset, total country programme expenses are
captured by expenditure category: local salaries; advertising and
promotion; and information, education and communication (IEC),
and are allocated across the range of public health products being
distributed. As an illustration PSI country programmes that were
distributing male condoms distributed on average four other prod-
ucts (range 0–19 additional products). Male condom programmes
are generally far larger than female condom programmes, with
mean female condom programme expenditures across these cat-
egories (IEC, advertising and local salaries) ranging from 6% to 9%
of male condom programme expenditures. The WDI  dataset con-
tribute population size, HIV prevalence, and per capita income. All
prices are adjusted to 2011 purchasing power parity (PPP) dollars
($).
Appendix 1 provides an overview of the data availability across
countries and years and the descriptive statistics of the full data set,
including the percentage of observations that were dropped in the
static estimation.
Fig. 1 presents the sales quantities of male and female condoms
over time. Generally, an increasing trend can be seen, with more
3 The number of country programmes increased over time.
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Table 1
Summary statistics.
Variable Deﬁnition, source Data source Male condom programme Female condom programme
Mean*
(Min–Max)
Fraction of zero
values
Mean*
(Min–Max)
Fraction of zero
values
Demand Condom quantity sold PSI 16,729,476.84 163,801
(249–197,030,442) (26–4,238,960)
Price  Condom price PSI $0.09 4.5% $0.36 14.3%
($0–$0.65) ($0–$4.14)
Programme effort Local salary expenditure PSI $1,082,587 1% $115,202 9.8%
($0–$17,580,319) ($0–$1,159,756)
Advertising Advertising expenditures
Advertising refers to mass media
promotion strategies
PSI $776,628 3.7% $64,832 28.6%
($0–$7,897,325) ($0–$690,505)
Information & Education
Campaign
IEC expenditures
IEC refers to one-on-one or small
group intra-personal communication
promotion strategies
PSI $491,159 22.0% $297,789 33.8%
($0–$12,362,417) ($0–$441,515)
Promotion IEC expenditures + advertising
expenditures
PSI $1,267,788 1.6% $95,338 19.5%
($0–$15,761,431) ($0–$690,505)
Product maturity Years of condom product sales PSI 8.13 4.43
(0.2–24) (1–13)
HIV  adult prevalence Prevalence of HIV in the adult
population
WDI  5.64% 8.27%
(0.10%–28.70%) (0.10%–28.60%)
GDP  per capita GDP per capita WDI  $3.642 $3.489
($548–$18,032) ($583–$14,023)
Population Size Population size (in millions) WDI  55.82 55.87
(47.73–71.49) (48.55–69.44)
n  382 133
A
P rganis
w
C
t
o
a
4
4
p
c* Values are presented in natural units (not logarithms).
ll  prices are presented in 2011 purchasing power parity dollars.
SI: Population Services International programme accounts, the social marketing o
idespread and larger scale male – than female – condom sales.
ondoms sold by region over time can be found in Fig. A1. Africa has
he highest distribution of all condoms, with a substantial number
f male condoms distributed in Asia, while few female condoms
re distributed outside of Africa.
. Estimation strategy
.1. Static analysis to compare drivers of demand between
roducts
We  start with a static model of the demand for male and female
ondoms to test for differences between their responsiveness to
 -
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Fig. 1. Condom sales by produation. WDI: World Development Indicators database.
the various demand determinants. We estimate static pooled OLS
and ﬁxed effects models where we  include intercept and slope
dummies to distinguish between female and male condoms as fol-
lows:
ln(qkit) =  ˛ + FC +
∑
j
ˇj ln(Xj
kit
) +
∑
j
jFC ∗ ln(Xj
kit
)
+ i + ωt + εkit, k = 1, 2; i = 1, . . .,  N; t = 1, . . .,  Twhere k, i and t index respectively: product type (female or male
condoms), country and time period, and FC is a dummy variable
taking the value one if the product is female condom and zero oth-
erwise. As already enumerated in Section 2, the full set of variables
 -
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nal of
t
I
r
r
u
t
y
g
t
t
v
4
d
a
l
w
k
b
w
ﬁ
a
u
v
d
i
l
f
e
v
a
f
p
d
e
f
a
c
E
l
d
e
o
w
i
p
b
i
i
i
t
x
c
p
v
for both products (not shown).
The static ﬁxed effects model suggests considerable differences
between male and female condom demand responses, with femaleF. Terris-Prestholt, F. Windmeijer / Jour
o be explored is: Price of condoms, Promotion (or Advertising and
EC) and Programme effort, Income, HIV prevalence, Product matu-
ity, and Population size. The i and ωt are country and time effects,
espectively. The country ﬁxed effects absorb the effects of any
nobserved country characteristics, such as geography and cul-
ure. The time ﬁxed effects capture the impacts of factors such as
early ﬂuctuations in funding ﬂows that may  affect all country pro-
rammes and both product types in a certain time period. Given
he strain on degrees of freedom, we will also estimate an alterna-
ive speciﬁcation of the time ﬁxed effect by including just a trend
ariable.
.2. Dynamic models of demand
Following our discussion in Section 2, a dynamic model of
emand for each product (female or male condom) can be speciﬁed
s follows:
n(qi,t) =  ˛ +
∑
j
ˇj ln(Xj
i,t
) +  ln(qi,t−1) + i + ωt + εi,t,
i = 1. . .N; t = 1. . .T
here variables and coefﬁcients are deﬁned as above. As is well
nown, the OLS and ﬁxed effects estimators for  are expected to be
iased upwards and downwards, respectively, the latter especially
ith a short time series dimension T as we have here. Thus the
xed effects estimator is likely to imply a higher rate of annual
dvertising depreciation (thus a smaller ) compared to estimation
sing pooled OLS (Blundell et al., 2000).
The generalised methods of moments (GMM)  estimator pro-
ides a consistent estimation framework for dynamic panel
ata models (Arellano and Bond, 1991). With GMM,  the model
s ﬁrst-differenced to remove the country effects i. Then
n(qi,t−2), ln(qi,t−3), . . .,  ln (qi1) can be used as valid instruments
or the lagged sales difference [ln(qi,t−1) − ln(qi,t−2)], which is
ndogenous in the ﬁrst-differenced model. The instruments are
alid as E[(εi,t − εi,t−1) {ln(qi,t−2), ln(qi,t−3), ..., ln(qi1)}] =0, under the
ssumption that the εi,t are serially uncorrelated.
It has been shown that the Arellano and Bond estimator suf-
ers from ﬁnite sample weak instruments bias when the series are
ersistent (Blundell et al., 2000). To mitigate this problem Blun-
ell and Bond proposed the ‘system’ (SYS) GMM  estimator, which
stimates the parameters based on a combination of levels and dif-
erences. Speciﬁcally, the SYS-GMM employs the lagged differences
s instruments for the equations in levels, assuming that initial
onditions, like mean-stationarity, are in place such that
[(vi + εi,t) ln(qi,t−1)] = 0.
The main disadvantage of the GMM  estimation approach is the
oss of degrees of freedom. This loss of degrees of freedom is not ran-
om: the early years of a sample, which often represent new market
ntry, are lost. The GMM  estimator quantiﬁes advertising effects
nly in the more mature markets because it includes only groups
ith three or more years of sales history. It can thus not provide
nformation on the relative value of advertising in early years of a
roduct’s history. Moreover the number of potential instruments
ecomes large when there are many time periods and variables;
t is therefore recommended to limit the number of instruments
ncluded. The one-step system GMM  estimator using sequential
nstruments dated t − 2 to t − 3 is used to estimate the parame-
ers of the dynamic panel data model (4), using Stata command
tabond2 (Roodman, 2009).As the marketing tool variables include zero values, i.e. when
ondoms are distributed freely or there were no expenditures for
romotion or local staff, we assign a small value (0.1) to these obser-
ations before taking logs, and include binary indicator variables for Health Economics 48 (2016) 107–120 111
those observations.4 The GMM  estimates are then used to estimate
the long-run effects of the demand stimulation tools on sales, Eq.
(1). The variances of these long-run effects are estimated using the
delta method; in STATA this is done using the ‘nlcom’ post esti-
mation command. We use these to evaluate the signiﬁcance of the
long-run elasticities.
As we mentioned above, prices, promotion and programme
effort are determined by country ofﬁces. After controlling for coun-
try and time ﬁxed effects, the endogeneity of these variables with
respect to demand shocks is limited as normal market forces are
not at work here. There may  of course be some slow responses
to demand shocks, but we  assume that they are such that εi,t and
εi,t−1 do not affect current and one-period lagged prices, promotion
and programme efforts. Under this assumption, the GMM  estima-
tor, only controlling for the endogeneity of lagged demand, will
consistently estimate the short- and long-run effects.
Our dynamic panel data framework allows us to treat all vari-
ables as endogenous, but at a cost of weaker identiﬁcation and an
increasing number of instruments. As a robustness check, we also
estimate the dynamic model parameters by GMM,  treating prices,
promotion and programme effort as endogenous, using lagged lev-
els dated t − 2 and t − 3 as instruments for the ﬁrst-differences and
lagged changes dated t − 1 as instruments for the levels.
5. Empirical results
5.1. Main results
As already discussed our aim is to understand the drivers of
demand and whether they vary by product, in order to inform
the appropriate approach to demand stimulation (i.e. which type
of marketing tool will give the greatest increase in sales per dol-
lar spent). Table 2 presents the results of the static pooled OLS
and ﬁxed effects models with female condom dummy  variables
to test for differences in the determinants of demand. The pooled
OLS model is rejected in favour of the FE model allowing for esti-
mated country ﬁxed effects; we  therefore focus on the FE estimates.
The Log-likelihood Ratio (LR) test could not reject the year trend in
favour of the 10 year-speciﬁc effects; as such time is captured by a
trend in the presented models. The results with alternative speciﬁ-
cations of the time effects are presented in Appendix Table A5. The
results are very similar, though the IEC*female condom interaction
variable loses signiﬁcance in the alternative speciﬁcation.
Country effects and coefﬁcients for the ‘Year’ trend and ‘No
expenditures’ dummies (No advertising, No local salaries, No IEC,
free products, respectively) are not presented. Table A6 presents
the same model run separately for Male and Female condoms,
but including HIV prevention substitutes in the marketing mix
(female condoms as substitutes for male condom, and the price
of substitutes (the price of male condoms as a driver of demand for
female condoms).
The signs of the marketing coefﬁcients conform to expecta-
tions: Advertising, IEC and Programme Effort all have positive signs
while Price has a negative sign. In the ﬁxed effects model Price
and Programme Effort are not signiﬁcant at conventional levels of
signiﬁcance.5 Price does however have a signiﬁcant negative effect
(elasticity −0.453, p < 0.00) on condom sales when estimated jointly4 The magnitude of the ‘small value’ does not affect the estimates in any way.
5 To explore the possibility that price is driven by country ﬁxed effects, we have
run a regression of price on country- and year-speciﬁc ﬁxed effects. The coefﬁcient
of  determination is very low (r-squared = 0.31) suggesting otherwise.
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Table 2
Estimation results: static model of the demand for condoms.
Dependent variable:
Ln country condom sales
(1) (2)
Pooled OLS Fixed effects
Variables Year as trend Year as trend
Constant 21.330 (30.68) −84.41 (62.11)
Female condom dummy  (FC) 2.423 (2.215) 0.385 (1.996)
Ln  advertising 0.241*** (0.085) 0.192*** (0.067)
*FC −0.199* (0.116) −0.192* (0.101)
Ln  IEC 0.124*** (0.044) 0.081** (0.032)
*FC 0.162 (0.121) 0.176* (0.105)
Ln  own  price −0.230*** (0.076) −0.123 (0.100)
*FC −0.246* (0.143) −0.179 (0.133)
Ln  programme effort 0.231*** (0.075) 0.131 (0.081)
*FC −0.148 (0.194) −0.035 (0.178)
Ln  GDP per capita 0.108 (0.096) −0.530 (0.407)
*FC 0.002 (0.198) 0.146 (0.188)
Ln  population size 0.407*** (0.050) −0.036 (1.293)
*FC −0.242** (0.114) −0.317*** (0.122)
Ln  adult HIV prevalence 0.055* (0.033) 0.445* (0.259)
*FC 0.282** (0.112) 0.336*** (0.097)
Ln  product maturity 0.484*** (0.075) 0.383** (0.150)
*FC 0.004 (0.193) −0.048 (0.243)
Year  −0.011 (0.015) 0.050 (0.039)
Observations 515 515
R-squared 0.865 0.930
LR-test  (H0: no country effects) 335***
Robust standard errors (clustered by country) in parentheses.
* p < 0.1.
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ondoms being more responsive than male condoms to: IEC, Pop-
lation size and HIV prevalence and less (to the point of not at all)
esponsive to mass media advertising.
This static approach is arguably satisfactory for exploring dif-
erences in the determinants of demand by product. However,
s discussed in the previous section, demand is expected to be
riven not only by current marketing strategies, but also by pre-
ious period investments. In such cases a dynamic model is more
ppropriate. A one-step system GMM  estimator is used to esti-
ate the short- and long-run effects of promotion, prices and
rogramme effort and country contexts and the duration of their
ffects (Table 3). ‘Promotion’ is here deﬁned as the sum of mass
edia advertising and IEC as estimation of separate effects led to
nstable results.
The speciﬁcation tests for the GMM  estimator are satisﬁed, i.e.
e ﬁnd 1st order serial correlation (ar1), albeit slightly above con-
entional p-values, and no 2nd order serial correlation (ar2). The
ansen test does not reject the over-identifying conditions. The
arge Hansen p-value for the female condom estimates is caused
y the small sample size. Conforming to expectations, the system
MM  estimate for  lies between the OLS and FE estimates.
Qualitatively, the three estimators provide reasonably consis-
ent results, particularly for male condoms and for the presence of
ersistence and effectiveness of promotion for increasing demand.
n contrast to the signiﬁcantly positive coefﬁcient on population
ize in the GMM  model, the OLS and ﬁxed effects models did not
dentify this effect.
Both the male and female condom display signiﬁcant persis-
ence, with male condom demand slower to adjust to stimuli than
emale condom demand, as seen in the relatively higher  in the
ale condom estimates (0.570) relative to the female condom esti-
ates (0.347). It takes 3.1 and 1.2 years for 90% of the cumulative
ffects to be exhausted, respectively, for male and female condoms.
Short- and long-run male condom demand is driven largely by
romotion, price and population size. The GMM  estimates showthat the short-run impact of a 10% increase in promotion spend-
ing is 1.66%, whereas such an investment is expected to increase
demand by 3.85% in the long-run. A 10% increase in price is
expected to generate a 0.82% decrease in male condom demand
in the short-run, increasing to 1.92% in the long-run. Programme
effort has no immediate or long-run effect. It can be further seen
that income, as proxied by GDP per capita, and product matu-
rity or HIV prevalence do not signiﬁcantly affect male condom
demand.
In the female condom ﬁxed effects model all coefﬁcients lose
signiﬁcance except product age and promotion which is likely
attributable to the small sample size. Demand for female con-
doms changes more rapidly than demand for the male condom
( = 0.347). The short-run effect of a 10% increase in promotion
spending is 1.78% rising to 2.72% in the long-run. Price has a very
large effect on demand, with a 10% price increase leading to a
3.60% and a 5.51% decrease in demand in the short- and long-run,
respectively. In contrast to male condom demand, female condom
demand is affected by HIV prevalence in both the short- and long-
run.
5.2. Robustness checks
As robustness checks, for the demand for male condoms we
have estimated these relationships under a variety of alternative
GMM speciﬁcations. One speciﬁcation excludes Eastern European
which and Central Asian countries from the estimation sample.
Another treats prices, promotion and programme efforts as endoge-
nous, as described above. These speciﬁcations do not qualitatively
change the results (see Table A8). Estimation of the ‘ordinary’ ﬁrst-
differenced GMM  did result in considerably different results (see
Table A8). The model with instrumented prices, promotion and
programme effort shows a higher rate of persistence ( = 0.714),
and higher short-run and long-run promotion and price elastici-
ties (short-run 0.208 and −0.111, long-run: 0.727 and −0.387). As
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Table  3
Estimation results: dynamic panel data model of the demand for condoms.
Dependent variable:
Ln country condom sales
Dynamic male condom estimates Dynamic female condom estimates
Variables OLS Fixed effects GMM  OLS Fixed effects GMM
Lag Ln condom sales 0.755*** 0.540*** 0.570*** 0.451*** 0.186 0.347***
(0.0792) (0.123) (0.113) (0.114) (0.188) (0.124)
Ln  promotion 0.160*** 0.139*** 0.166*** 0.166* 0.165* 0.178**
(0.0514) (0.0518) (0.0612) (0.0875) (0.0889) (0.0874)
Ln  price −0.0524 −0.172*** −0.0826* −0.335** −0.171 −0.360***
(0.0538) (0.0608) (0.0490) (0.120) (0.108) (0.110)
Ln  programme effort 0.0501 0.142 0.112 −0.0605 −0.122 −0.0513
(0.0700) (0.115) (0.0885) (0.102) (0.126) (0.0798)
Ln  GDP per capita −0.00652 0.207 −0.00341 −0.0123 −0.818 0.00253
(0.0712) (0.383) (0.0773) (0.170) (3.057) (0.188)
Ln  product age −0.0456 −0.117 0.0872 0.178 2.754* 0.344
(0.0683) (0.199) (0.113) (0.303) (1.348) (0.333)
Ln  population size 0.0569 1.554 0.148** 0.177 −12.50 0.185
(0.0618) (0.972) (0.0645) (0.124) (17.03) (0.116)
LN  adult HIV prevalence 0.00799 0.532*** 0.0189 0.173 0.188 0.215*
(0.0237) (0.192) (0.0262) (0.122) (0.793) (0.117)
ar1p  0.137 0.130
ar2p  0.521 0.390
hansenp 0.165 0.973
Long  term effects
Promotion 0.385** (0.161) 0.272** (0.145)
Price −0.192** (0.097) −0.551*** (0.152)
Programme effort 0.261 (0.177) −0.079 (0.127)
GDP  per capita −0.008 (0.180) 0.004 (0.29)
Product age 0.203 (0.227) 0.527 (0.446)
Population size 0.345*** (0.100) 0.283* (0.170)
Adult HIV prevalence 0.044 (0.062) 0.329** (0.154)
Observations 280 85
R-squared 0.889 0.570 0.761 0.616
Number of countries 58 26
Robust standard errors in parentheses.
Parameters for the constant, year, country and dummy’s for no promotion, free condoms and no stafﬁng are not shown, but available upon request.
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iscussed, this speciﬁcation has weaker identiﬁcation due to the
nstrumentation of all the variables, which also leads to quite a
arge number of instruments, relative to the sample size, may  bias
he estimates.
For the original speciﬁcation, the results did not change when
dding qi,t−4 as a further instrument for the differences (not shown).
ecause Zimbabwe had far higher female condom sales than
he other countries and contributed 10% of the observations, we
emoved its observations to check for its inﬂuence on the results;
gain the results remain broadly intact when excluding Zimbabwe
not shown).
.3. Study limitations
Within the scope of HIV prevention products, the full substi-
ute market was not observed. We only analysed data on condom
ales through PSI; the free public sector was not incorporated
or was the private condom sector (in the few countries where
t existed). When considering condoms as contraceptives, there
xist both private and public markets for contraceptives in these
ountries, which were also not captured. We did however run our
tatic models capturing the price of PSI male condoms as the price
f substitute for female condoms and found no signiﬁcant effect,
hile programmes selling female condoms had signiﬁcantly higher
ale condom sales (Table A6). The study period covered the intro-
uction of HIV treatment in some countries. Though the general
rend is captured by the time dummies, ideally it would have been
ncluded in more detail. Other variables that theoretically should
ave been included were: Gini coefﬁcient (to account for aggrega-
ion bias in country level analyses), and age and sex distribution ofthe population (to capture the at-risk population). Complete time
series data on these variables across our sample countries were
not available and changed little over the study period, however the
country and time effects remove biases potentially introduced by
their omission.
Though this dataset is the largest of its kind that can be used
to estimate the effects of marketing tools on condom sales, it is
relatively small compared to many other analyses of advertising
and price elasticities of demand.
The social marketing data may  contain measurement error and
inconsistencies over time and countries attributable to the follow-
ing factors. While PSI has provided ﬁnancial data on the allocation of
costs from 1997 to 2009, it should be noted that during this time-
frame, PSI implemented a rolling upgrade of its ﬁnancial system,
which contributes to some variation in the data by country and year.
Reporting requirements by PSI funders sometimes vary, leading to
differences in allocations of costs between expenditure categories.
Allocations of shared expenditures across products may  not have
been applied consistently. The data do not differentiate between
generic and branded promotional expenditures. The measurement
error could lead to attenuation bias, which can then be part of the
reason why  we  ﬁnd bigger effects when treating all variables as
endogenous.
Despite these limitations, we  ﬁnd largely robust results, in par-
ticular for the male condom analysis. The female condom results
should be considered indicative rather than conclusive due to the
smaller sample size. These results are largely consistent with the lit-
erature of advertising impact, however given the products at hand
and the country settings, direct comparison of the magnitude of
demand elasticities is not productive.
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. Conclusions
This study aimed to evaluate the effectiveness of social market-
ng tools in stimulating demand for male and female condoms. It
ontributes to the literature by comparing their effects on prod-
cts targeting men  (male condoms) and products sold mainly to
omen (female condoms) and by estimating both short- and long-
un effects (allowing for condom use behaviour to adjust slowly)
sing a dynamic model that also controls for potential endogeneity.
We have shown that marketing tools do not have a consistent
mpact across condom types, in line with the contraception liter-
ture on oral contraceptive versus condoms (reviewed in Section
). Mass media advertising is an important marketing tool for male
ondoms. Advertising is however not found to be effective in stim-
lating demand for female condoms. IEC appears important for all
ondoms with a slightly stronger impact on female than male con-
oms. For both products, promotion and price have strong long-run
ffects, approximately doubling the short-run effects.
More research needs to be done to better understand the differ-
nces between the price elasticities of demand between the male
nd female condom; in particular to disentangle price and income
ffects: i.e. are the effects truly attributable to differences in price
evels and products, or are they more related to the user groups,
ith female condoms targeted particularly for purchase by women,
nown to have lower ability to pay. Care needs to be taken when
etting prices to ensure they remain consistent with social mar-
eting aims: i.e. sufﬁciently low to not form a barrier to demand,
hile reducing wastage, instilling a sense of value associated with
he products and reducing stigma (Brent, 2009, 2010).
The ﬁndings of this paper have a number of policy implica-
ions. Firstly, despite the fact that condoms remain one of the most
ost-effective approaches to preventing HIV (Schwartländer et al.,
011), the global HIV prevention community is increasingly look-
ng towards new HIV prevention products (Stover et al., 2014). This
tudy shows that with consorted effort including promotion and
ow product pricing, demand for condoms can be increased, with
asting effects, and should not be forgotten as part of a combination
revention approach to the HIV epidemic.
Secondly, our results provide guidance for developing demand
reation approaches for these new HIV prevention products: it
s important to consider the target user as well as the product
haracteristics. If sold, consideration to purchasing power of
he intended target users may  be critical to the scale of their
istribution, as well as the fact that the product price is only part
f the cost of product use; many people face high costs to access
ealth services, both in terms of direct transport costs and labour
ime lost. Social marketing can play a critical role in diversifying
istribution outlets to bring products to more accessible locations
nd in increasing demand and reduce product stigma through
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interpersonal communication and mass media advertising, while
complementing public sector free distribution to ensure access to
public health products for those with less ﬁnancial resources.
Finally, analyses of the impact of behaviour change interven-
tions need to consider that many changes in human behaviours,
in particular preventive ongoing behaviours, are slow to adjust.
Where appropriate data exist, estimating dynamic models, as done
in this analysis, should reduce the bias otherwise present and
improve the interpretation of coefﬁcients for policy applications.
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Table  A1
Summary statistics of full sample.
Variable Deﬁnition, source Male condom programme Female condom programme
N Mean* % of values dropped
in estimation
N *Mean % of values dropped
in estimation
(Min–Max) (Min–Max)
Demand Condom quantity
sold, PSI
430 15,900,000 10% 155 147,802 14%
(249–197,000,000) (26–4,238,960)
Price  Condom price, PSI 416 $0.10 7% 142 $0.37 6%
($0–$0.95) ($0–$4.14)
Programme effort Local salary
expenditures, PSI
416 $1,065,602 7% 145 $116,555 8%
($0–$17,600,000) ($0–$1,159,756)
Advertising Advertising
expenditures, PSI
416 $778,457 7% 145 $64,170 8%
Advertising refers
to mass media
promotion
strategies,
($0–$8,263,314) ($0–$690,505)
Information & Education
Campaign (IEC)
IEC expenditures,
PSI
416 $467,164 7% 145 $28,930 8%
IEC  refers to
one-on-one or
small group
intra-personal
communication
promotion
strategies
($0–$12,400,000) ($0–$441,515)
Promotion IEC expendi-
tures + advertising
expenditures, PSI
416 $1,240,311 7% 144 $93,746 8%
($0–$15,800,000) ($0–$690,505)
Product maturity Years of condom
product sales, PSI
430 8.89 10% 155 4.21 14%
(0.2–24) (1–13)
HIV  adult prevalence Prevalence of HIV
in  the adult
population, WDI
394 5.53% 2% 141 8.16% 6%
(0.10–28.70%) (0.10–28.70%)
GDP  per capita GDP per capita,
WDI
406 $4.150 5% 139 $3.576 4%
($548–$22,630) ($583–$14,023)
Population Size Population size (in
millions), WDI
406 66,700,000 5% 139 80,600,000 4%
(293,544–1,330,000,000) (301,016–1,330,000,000)
* Values are presented in natural units (not logarithms).
All  prices are presented in 2011 purchasing power parity dollars.
PSI: Population Services International programme accounts, the social marketing organisation. WDI: World Development Indicators database.
Sample used in the static estimation contains 382 observations for male condoms and 133 for female condoms. The dynamic estimator requires at least 3 years of data to
obtain  1 observation, because of the need for lags. The dynamic estimation thus had 280 male condom observations and 85 female condom observations.
Table A2
Overview of panel data structure (number of country’s programmes distributing
each condom type by year).
Year Male condom Female condom
1997 11 3
1998 21 4
1999 37 7
2000 36 9
2001 43 11
2002 43 15
2003 48 16
2004 44 19
2007 44 17
2008 51 26
2009 52 28
Total 430 155
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Table A3
Male condom data availability.
Country Year
1997 1998 1999 2000 2001 2002 2003 2004 2007 2008 2009
Afghanistan 1 1
Albania 1 1 1 1 1
Angola 1 1 1 1 1 1 1
Belize  1 1
Benin  1 1 1 1 1 1 1 1 1 1 1
Bolivia 1 1 1 1 1
Botswana 1 1 1 1 1 1 1 1 1
Burkina Faso 1 1 1 1 1 1 1
Burundi 1 1 1 1 1 1 1 1 1
Cambodia 1 1 1 1 1 1 1 1
Cameroon 1 1 1 1 1 1 1 1 1 1
Caribbean 1
Central African Republic 1 1 1 1 1 1 1 1
Central America 1 1 1 1 1 1 1 1
Chad  1 1 1
China 1 1 1 1
Congo (Dem. Rep. & Rep.) 1 1 1
Congo,  Dem. Rep. 1 1 1 1
Congo, Rep. 1 1 1 1
Costa  Rica 1 1
Cote  d’Ivoire 1 1 1 1 1 1 1 1 1 1 1
Cuba  1 1
Dominican Republic 1 1 1 1 1
El  Salvador 1 1
Eritrea 1 1 1 1 1 1
Ethiopia 1 1
Georgia 1 1 1 1
Guatemala 1 1
Guinea 1 1 1 1 1 1 1 1 1 1 1
Guinea-Bissau 1 1 1
Guyana 1
Haiti  1 1 1 1 1 1 1 1 1 1 1
Honduras 1 1
India  1 1 1 1 1 1 1 1 1 1 1
Kazakhstan 1 1 1 1 1
Kenya 1 1 1 1 1 1 1 1 1 1
Kosovo 1 1 1
Kyrgyzstan 1 1 1 1 1
Lao  PDR 1 1 1 1 1 1 1 1 1
Lesotho 1 1 1 1 1 1
Lesotho & Swaziland 1 1 1
Liberia 1
Madagascar 1 1 1 1 1 1 1 1 1
Malawi 1 1 1 1 1 1 1 1 1 1
Mali  1 1 1 1 1 1 1
Mexico 1 1 1
Mozambique 1 1 1 1 1 1 1 1 1 1
Myanmar 1 1 1 1 1 1 1 1 1
Namibia 1 1 1 1 1 1 1 1 1 1
Nepal  1 1
Nicaragua 1 1
Nigeria 1 1 1 1 1 1 1 1 1 1
Pakistan 1 1 1 1 1 1 1 1 1
Panama 1
Papua  New Guinea 1 1 1
Paraguay 1 1 1 1 1 1 1 1 1
Romania 1 1 1 1 1 1 1 1 1 1
Russian Federation 1 1 1 1 1 1 1 1 1 1
Rwanda 1 1 1 1 1 1 1 1 1 1
South  Africa 1 1 1 1 1 1 1 1 1 1
Sudan 1 1
Swaziland 1 1 1 1
Tajikistan 1 1 1 1
Tanzania 1 1 1 1 1 1 1 1 1
Thailand 1 1 1 1 1
Togo  1 1 1 1 1 1 1 1 1 1 1
Uganda 1 1 1 1 1 1 1 1 1
Uzbekistan 1
Vietnam 1 1 1
Zambia 1 1 1 1 1 1 1 1 1 1
Zimbabwe 1 1 1 1 1 1 1 1 1 1 1
Total  11 21 37 36 43 43 48 44 44 51 52
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Table  A4
Female condom data availability.
Country Year
1997 1998 1999 2000 2001 2002 2003 2004 2007 2008 2009
Belize 1
Benin 1 1
Bolivia 1 1 1 1 1
Botswana 1 1 1 1
Burkina Faso 1
Cambodia 1 1 1
Cameroon 1 1 1 1 1 1
Caribbean 1
Central African Rep. 1 1
Central America 1 1 1 1 1 1
China  1 1 1 1
Congo (Dem. Rep. & Rep.) 1
Congo,  Dem. Rep. 1 1
Congo, Rep. 1
Costa  Rica 1
Cote  d’Ivoire 1
El  Salvador 1 1
Guatemala 1 1
Guinea-Bissau 1 1
Haiti 1 1 1 1 1 1 1 1 1 1 1
India  1 1 1
Lesotho 1 1 1 1
Lesotho & Swaziland 1 1 1
Madagascar 1 1
Malawi 1 1
Mali  1 1 1 1 1 1
Mozambique 1 1 1 1 1 1 1 1
Myanmar 1 1 1 1 1
Namibia 1 1
Nicaragua 1 1
Nigeria 1
Papua New Guinea 1 1
Paraguay 1 1 1 0 0
South  Africa 1 1 1 1 1 1 1 1 1 1
Swaziland 1
Tanzania 1 1 1 1 1 1 1 1 1
Togo  1 1 1 1 1 1 1 1 1
Uganda 1
Vietnam 1 1 1
Zambia 1 1 1 1 1 1 1 1 1 1
Zimbabwe 1 1 1 1 1 1 1 1 1 1 1
Total  3 4 7 9 11 15 16 19 17 26 28
Table A5
Correlation matrix.
Ln
condom
sales
Ln
promotion
Ln
advertising
Ln
IEC
Ln
price
Ln
programme
effort
Ln
product
age
Substitute
(dummy)
Ln GDP
per
capita
Ln
population
size
Ln adult HIV
prevalence
Male condom (N = 382)
Ln male condom sales 1.00
Ln  promotion 0.30 1.00
Ln  advertising 0.32 0.70 1.00
Ln  IEC 0.16 0.26 0.09 1.00
Ln  price 0.13 0.09 0.24 −0.04 1.00
Ln programme effort 0.28 0.83 0.57 0.23 0.10 1.00
Ln  product age 0.53 0.02 0.07 0.22 0.05 0.06 1.00
Substitute (dummy) 0.21 0.08 0.06 0.22 0.01 0.05 0.16 1.00
Ln  GDP per capita −0.19 −0.07 −0.13 −0.02 −0.06 −0.06 −0.22 −0.01 1.00
Ln  population size 0.56 0.17 0.08 0.06 −0.11 0.14 0.24 −0.00 0.00 1.00
Ln  adult HIV prevalence 0.17 0.01 0.08 −0.04 −0.05 0.01 0.32 0.29 −0.24 −0.20 1.00
Female condom (N = 131)
Ln female condom sales 1.00
Ln  promotion 0.22 1.00
Ln  advertising 0.33 0.80 1.00
Ln  IEC 0.20 0.70 0.48 1.00
Ln  price 0.33 0.15 0.30 −0.02 1.00
Ln programme effort 0.19 0.45 0.34 0.39 0.06 1.00
Ln  product age 0.50 −0.08 0.07 0.14 0.21 −0.06 1.00
Substitute (dummy) −0.09 −0.03 0.10 −0.11 0.52 0.04 0.03 1.00
Ln  GDP per capita −0.18 −0.17 −0.11 −0.22 −0.36 −0.13 −0.12 −0.11 1.00
Ln  population size 0.16 0.01 0.03 −0.09 0.09 −0.10 0.05 0.02 −0.03 1.00
Ln  adult HIV prevalence 0.46 −0.06 −0.01 −0.05 0.23 −0.02 0.41 −0.17 −0.07 −0.14 1.00
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Table A6
Estimation results (robustness check): static model with year-speciﬁc effects.
Variables (1) (2) (3) (4)
OLS trend FE trend i.c OLS i.y FE i.y i.c
Constant 21.33 −84.41 −0.816 18.03
(30.68) (62.11) (1.354) (19.35)
Female condom dummy  2.423 0.385 2.543 0.349
(2.215) (1.996) (2.205) (1.975)
Ln  Advertising 0.241*** 0.192*** 0.245*** 0.192***
(0.0846) (0.0665) (0.0858) (0.0665)
*FC −0.199* −0.192* −0.211* −0.196*
(0.116) (0.101) (0.116) (0.1000)
Ln  IEC 0.124*** 0.0812** 0.136*** 0.0893***
(0.0444) (0.0315) (0.0451) (0.0334)
*FC 0.162 0.176* 0.136 0.148
(0.121) (0.105) (0.125) (0.107)
Ln  Own  Price −0.230*** −0.123 −0.242*** −0.129
(0.0763) (0.100) (0.0789) (0.0987)
*FC −0.246* −0.179 −0.274* −0.201
(0.143) (0.133) (0.146) (0.134)
Ln  Programme Effort 0.231*** 0.131 0.211*** 0.120
(0.0752) (0.0813) (0.0765) (0.0826)
*FC −0.148 −0.0349 −0.144 −0.0424
(0.194) (0.178) (0.190) (0.176)
Ln  GDP per capita 0.108 −0.530 0.126 −0.555
(0.0963) (0.407) (0.0991) (0.416)
*FC 0.00248 0.146 −0.00630 0.149
(0.198) (0.188) (0.199) (0.186)
Ln  Population Size 0.407*** −0.0364 0.409*** −0.207
(0.0501) (1.293) (0.0499) (1.332)
*FC −0.242** −0.317*** −0.230** −0.298**
(0.114) (0.122) (0.113) (0.121)
Ln  Adult HIV prevalence 0.0547* 0.445* 0.0525 0.503*
(0.0327) (0.259) (0.0331) (0.284)
*FC 0.282** 0.336*** 0.281** 0.333***
(0.112) (0.0972) (0.114) (0.0980)
Ln  product maturity 0.484*** 0.383** 0.493*** 0.372**
(0.0752) (0.150) (0.0739) (0.149)
*FC 0.00396 −0.0477 0.0131 −0.0269
(0.193) (0.243) (0.193) (0.246)
Year  −0.0112 0.0496
(0.0153) (0.0390)
Observations 515 515 515 515
R-squared 0.865 0.930 0.868 0.931
LR-test 2 versus 1 3 versus 1 4 versus 2
335*** 12.2 12.8
Robust standard errors in parentheses.
* p < 0.1.
** p < 0.05.
*** p < 0.01.
Table A7
Estimation results: static model including substitutes/substitute price.
Dependent variable Ln quantity Male condom, FE Female condom, FE
Ln advertising 0.194*** (−0.069) −0.0486 (−0.121)
Ln  IEC 0.087*** (−0.029) 0.299** (−0.127)
Ln  own  price −0.143 (−0.099) 0.0959 (−0.165)
Substitute dummy; Ln Psubstitute for FC model 0.328*** (−0.103) −1.733 (−2.698)
Ln  programme effort 0.096 (−0.081) 0.0832 (−0.123)
Ln  GDP per capita −0.119 (−0.357) −4.247* (−2.151)
Ln  population size −0.788 (−1.134) 12.81 (−8.678)
Ln  adult HIV prevalence 0.665*** (−0.229) 1.513* (−0.843)
Ln  product maturity 0.523*** (−0.121) 0.541 (−0.489)
Year  0.0129 (0.036) −0.090 (0.136)
Constant −2.494 (−56.52) 12.41 (−204.4)
Observations 381 132
R-squared 0.9 0.854
Robust standard errors in parentheses.
* p < 0.1.
** p < 0.05.
*** p < 0.01.
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Table  A8
Robustness checks of the dynamic male condom model under alternative speciﬁcations.
Variables Base: systems GMM  1st-differenced GMM  Lags 2–4 Excl. EurAsia Endogenous price, promotion
and programme effort
Lag Ln condom sales 0.503*** −0.125 0.503*** 0.844*** 0.714***
(0.135) (0.208) (0.135) (0.0957) (−0.0892)
Ln  promotion 0.165** 0.0602 0.162** 0.135* 0.208***
(0.0664) (0.0516) (0.0664) (0.0726) (−0.0764)
Ln  price −0.0845 −0.0383 −0.0857 −0.0510 −0.111*
(0.0525) (0.0934) (0.0522) (0.0475) (−0.0651)
Ln  programme effort 0.128 −0.0187 0.128 −0.00286 0.0185
(0.0881) (0.226) (0.0876) (0.0599) (−0.0989)
Ln  GDP per capita −0.00420 1.114 −0.00406 0.0217 0.0295
(0.0798) (0.957) (0.0798) (0.0626) (−0.076)
Ln  product age 0.102 0.0650 0.103 −0.0984 −0.0168
(0.131) (0.453) (0.131) (0.101) (−0.0879)
Ln  population size 0.191** 1.838 0.192*** 0.0400 0.0665
(0.0746) (2.547) (0.0747) (0.0471) (−0.074)
Ln  adult HIV prevalence 0.0205 0.372 0.0206 0.0217 0.00765
(0.0292) (0.268) (0.0294) (0.0211) (−0.0248)
Iyear 1998 0.0326 0.0317 −0.00573
(0.137) (0.136) (−0.119)
Iyear 1999 0.250 0.0805
(0.183) (0.111)
Iyear 2000 −0.237** 0.255 −0.237** −0.177* −0.275***
(0.106) (0.274) (0.106) (0.0974) (−0.0999)
Iyear 2001 −0.0177 0.489 −0.0169 −0.0180 −0.0116
(0.115) (0.341) (0.115) (0.0793) (−0.105)
Iyear 2002 −0.0805 0.510 −0.0800 0.0309 −0.0856
(0.113) (0.454) (0.113) (0.104) (−0.108)
Iyear 2003 −0.113 0.596 −0.113 −0.0558 −0.12
(0.0967) (0.551) (0.0965) (0.0842) (−0.0885)
Iyear 2004 0.0335 0.660 0.0328 0.0412 0.044
(0.116) (0.650) (0.116) (0.0883) (−0.112)
Iyear 2008 −0.0391 0.257** −0.0402 0.109 0.0452
(0.165) (0.127) (0.167) (0.146) (−0.116)
Iyear 2009 −0.375** −0.375** −0.279** −0.333**
(0.164) (0.164) (0.110) (−0.135)
Constant 0.534 0.537 0.0831 0.0652
(1.108) (1.113) (0.803) (−1.053)
ar1  p-value 0.128 0.786 0.126 0.0175 0.159
ar2  p-value 0.514 0.428 0.517 0.514 0.435
Sargan p-value 0.0937
Hansen p-value 0.201 0.319 0.289 1.00
Observations 280 190 280 267 280
Number of countries 58 46 58 53 58
Long-run effects
Ln Promotion 0.332** 0.054 0.327** 0.332** 0.727*
(0.155) (0.045) (0.154) (0.155) (0.392)
Ln  rice −0.170* −0.034 −0.172* 0.170* −.387
(0.090) (0.086) (0.090) (0.09) (0.231)
Ln  programme effort 0.257* −0.017 0.258* 0.257 0.065
(0.149) (0.199) (0.149) (0.085) (0.334)
Ln  GDP per capita −0.008 0.990 −0.008 −0.008 0.103
(0.161) (0.898) (0.161) (0.161) (0.264)
Ln  product age 0.206 0.058 0.206 0.206 −0.058
(0.220) (0.398) (0.220) (0.22) (0.318)
Ln  population size 0.385*** 1.633 0.387*** 0.385*** 0.232
(0.385) (2.355) (0.089) (0.089) (0.213)
Ln  adult HIV prevalence 0.041 0.330 0.041 0.041 0.027
(0.058) (0.196) (0.058) (0.058) (0.088)
Robust standard errors in parentheses.
* p < 0.1.
** p < 0.05.
C price,
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A
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